title: Consumer Willingness to Pay for Dengue Vaccine (CYD-TDV, Dengvaxia®) in Brazil; Implications for Future Pricing Considerations.
abstract: Introduction and Objective:Dengue virus is a serious global health problem with an estimated 3.97 billion people at risk for infection worldwide. In December 2015, the first vaccine (CYD-TDV) for dengue prevention was approved in Brazil, developed by Sanofi Pasteur. However, given that the vaccine will potentially be paid via the public health system, information is need regarding consumers' willingness to pay for the dengue vaccine in the country as well as discussions related to the possible inclusion of this vaccine into the public health system. This was the objective of this research.Methods: We conducted a cross-sectional study with residents of Greater Belo Horizonte, Minas Gerais, about their willingness to pay for the CYD-TDV vaccine.Results: 507 individuals were interviewed. These were mostly female (62.4%) had completed high school (62.17%), were working (74.4%), had private health insurance (64.5%) and did not have dengue (67.4%). The maximum median value of consumers' willingness to pay for CYD-TDV vaccine is US$33.61 (120.00BRL) for the complete schedule and US$11.20 (40.00BRL) per dose. At the price determined by the Brazil's regulatory chamber of pharmaceutical products market for the commercialization of Dengvaxia®for three doses, only 17% of the population expressed willingness to pay for this vaccine.Conclusion: Brazil is currently one of the largest markets for dengue vaccine and the price established is a key issue. We believe the manufacturer should asses the possibility of lower prices to reach a larger audience among the Brazilian population.
authors.affiliation: Programa de Pós-graduação em Medicamentos e Assistência Farmacêutica, Faculdade de Farmácia, Universidade Federal de Minas GeraisBelo Horizonte, Brazil; SUS Collaborating Centre for Technology Assessment and Excellence in Health, Faculdade de Farmácia, Universidade Federal de Minas GeraisBelo Horizonte, Brazil.
authors.forename: Isabella P
authors.initials: IP
authors.lastname: Godói
authors.affiliation: Programa de Pós-graduação em Medicamentos e Assistência Farmacêutica, Faculdade de Farmácia, Universidade Federal de Minas Gerais Belo Horizonte, Brazil.
authors.forename: André S
authors.initials: AS
authors.lastname: Santos
authors.affiliation: Department of Statistics, Exact Sciences Institute, Universidade Federal de Minas Gerais Belo Horizonte, Brazil.
authors.forename: Edna A
authors.initials: EA
authors.lastname: Reis
authors.affiliation: SUS Collaborating Centre for Technology Assessment and Excellence in Health, Faculdade de Farmácia, Universidade Federal de Minas GeraisBelo Horizonte, Brazil; Programa de Pós-graduação em Saúde Pública, Faculdade de Medicina, Universidade Federal de Minas GeraisBelo Horizonte, Brazil.
authors.forename: Livia L P
authors.initials: LL
authors.lastname: Lemos
authors.affiliation: Programa de Pós-graduação em Medicamentos e Assistência Farmacêutica, Faculdade de Farmácia, Universidade Federal de Minas Gerais Belo Horizonte, Brazil.
authors.forename: Cristina M R
authors.initials: CM
authors.lastname: Brandão
authors.affiliation: Programa de Pós-graduação em Medicamentos e Assistência Farmacêutica, Faculdade de Farmácia, Universidade Federal de Minas GeraisBelo Horizonte, Brazil; SUS Collaborating Centre for Technology Assessment and Excellence in Health, Faculdade de Farmácia, Universidade Federal de Minas GeraisBelo Horizonte, Brazil.
authors.forename: Juliana
authors.initials: J
authors.lastname: Alvares
authors.affiliation: Programa de Pós-graduação em Medicamentos e Assistência Farmacêutica, Faculdade de Farmácia, Universidade Federal de Minas GeraisBelo Horizonte, Brazil; SUS Collaborating Centre for Technology Assessment and Excellence in Health, Faculdade de Farmácia, Universidade Federal de Minas GeraisBelo Horizonte, Brazil.
authors.forename: Francisco A
authors.initials: FA
authors.lastname: Acurcio
authors.affiliation: Strathclyde Institute of Pharmacy and Biomedical Sciences, Strathclyde UniversityGlasgow, UK; Division of Clinical Pharmaclogy, Karolinska Institutet, Karolinska University HospitalStockholm, Sweden.
authors.forename: Brian
authors.initials: B
authors.lastname: Godman
authors.affiliation: Programa de Pós-graduação em Medicamentos e Assistência Farmacêutica, Faculdade de Farmácia, Universidade Federal de Minas GeraisBelo Horizonte, Brazil; SUS Collaborating Centre for Technology Assessment and Excellence in Health, Faculdade de Farmácia, Universidade Federal de Minas GeraisBelo Horizonte, Brazil.
authors.forename: Augusto A
authors.initials: AA
authors.lastname: Guerra Júnior
keywords: Brazil; consumers; dengue; vaccine; willingness to pay